American Journal of Cardiology
Volume 103, Issue 3 , Pages 387-392 , 1 February 2009

Effect of Combination Nicotinic Acid and Gemfibrozil Treatment on Intermediate Density Lipoprotein, and Subclasses of Low Density Lipoprotein and High Density Lipoprotein in Patients With Combined Hyperlipidemia

  • H. Robert Superko, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • Cholesterol, Genetics, and Heart Disease Institute, Portola Valley, California
    • Corresponding Author InformationCorresponding author: Tel: 678-843-6052; fax: 678-843-6051
    • ,
  • Brenda C. Garrett, RN

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • ,
  • Spencer B. King III, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • ,
  • Kathryn M. Momary, PharmD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • ,
  • Nicolas A. Chronos, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • ,
  • Peter D. Wood, PhD, DSc

      Affiliations

    • Stanford University School of Medicine, Stanford, California

Received 30 May 2008 ,Revised 12 September 2008 ,Accepted 12 September 2008.

References 

  1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease (II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia). J Clin Invest. 1973;52:1544–1568
  2. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1993;13:427–434
  3. Krauss RM. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J. 1987;113:578–582
  4. Johansson J, Carlson LA, Landow C, Hamsten A. High density lipoproteins and coronary atherosclerosis (A strong inverse relation with the largest particles is confined to normotriglyceridemic patients). Arterioscler Thromb Vasc Biol. 1991;11:174–1825
  5. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD. Differential effect of gemfibrozil in normolipemic subjects with predominantly dense or buoyant low density lipoprotein particles and the effect on postprandial lipemia and Lp(a). Am J Cardiol. 2005;96:1266–1272
  6. Superko HR, McGovern ME, Raul E, Garrett B. Nicotinic acid has a differential effect on low density lipoprotein subclass distribution in patients classified as LDL pattern A, B, or I. Am J Cardiol. 2004;94:588–594
  7. Brown GB, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  8. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al. Change in a1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:847–852
  9. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug (A 50th anniversary review). J Intern Med. 2005;258:94–114
  10. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001;3:83–92
  11. United States Department of Health, Education, and Welfare. Lipid Research Clinics Manual of Laboratory Operations: Lipid and Lipoprotein Analysis, Vol. I. HEW Publication No. NIH 75-628. Washington, District of Columbia: United States Government Printing Office; 1974;
  12. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982;28:1379–1388
  13. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In:  Nelson GJ editors. Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York: Wiley-Interscience; 1972;p. 181–274
  14. Hogle DM, Smith RS, Curtiss LK. Quantitation of plasma apolipoprotein A-I using two monoclonal antibodies in an enzyme-linked immunosorbent assay. J Lipid Res. 1988;29:1221–1229
  15. Young SG, Smith RS, Hogle DM, Curtiss LK, Witztum JL. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem. 1986;32:1484–1490
  16. St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol. 2006;97:997–1001
  17. Whtney EJ, Krasuski RA, Personium BE, Michalek JE, Maranian AM, Kolasa MW, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95–104
  18. Superko HR. Lipoprotein subclasses and atherosclerosis. Front Biosci. 2001;6:d355–d365
  19. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762–2770
  20. Gardner CD, Fortmann SP, Krauss RM. Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875–881
  21. Stampfer MJ, Krauss RM, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–888
  22. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men (Prospective results from the Quebec cardiovascular study). Circulation. 1997;95:69–75
  23. Miller NE, Hammett G, Saltissi S, Rao S, Zeller HV, Coltart J, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J. 1981;282:1741–1744
  24. Superko HR, Krauss RM, Alderman EM. Diabetics have rapid arteriographic coronary disease progression but also arteriographic benefit from risk reduction. Circulation. 1997;96:4289
  25. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992;95:69–76
  26. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432–437
  27. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using TC/HDLC ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med. 2006;259:455–461
  28. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16:763–772

 This study was supported by Parke-Davis Pharmaceuticals, Warner-Lambert Company, Morris Plains, New Jersey, and the Cholesterol, Genetics, and Heart Disease Institute, Portola Valley, California.

PII: S0002-9149(08)01712-8

doi: 10.1016/j.amjcard.2008.09.103

American Journal of Cardiology
Volume 103, Issue 3 , Pages 387-392 , 1 February 2009

Article Tools

* Image Usage & Resolution